MiniMed Q1 sales rose; UBS lifts price target to $28
MiniMed Group reported Q1 FY2027 net sales of $843M, up 16.6% (15.8% organic). UBS raised its price target to $28 and reiterated a Buy, citing U.S. and international organic growth.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.